Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Cataract
Share your love
AAO 2026 Highlights Hospital Ophthalmology Coverage Gaps and Growing Reimbursement Pressures
Access to hospital-based eye care and reimbursement were policy topics at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, where ophthalmology leaders described a retrospective review of 747 eye-related transfers from 25 hospitals in the New York area. The…
Eyestem Research Presents Eyecyte-RPE Cell Therapy Data in Geographic Atrophy at EURETINA 2026
Eyestem Research presented clinical data for Eyecyte-RPE, an investigational retinal pigment epithelium (RPE) cell therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD), at EURETINA 2026 in Vienna. A mean best-corrected visual acuity (BCVA) gain of about…
Sight Sciences Introduces OMNI Ultra Surgical System at AAO 2026
Sight Sciences announced on October 1, 2026 that it would debut its OMNI Ultra Surgical System, the latest version of its implant-free minimally invasive glaucoma surgery (MIGS) platform, at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting in New…
SpyGlass Pharma Acquires Advanced Vision Science to Advance Drug-Eluting IOL Technology for Glaucoma
SpyGlass Pharma announced on October 1, 2026 that it has acquired Advanced Vision Science (AVS), its existing intraocular lens (IOL) manufacturer, for about $13 million. The deal gives SpyGlass direct control over a key component of its investigational BIM-IOL system,…
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials | Ophthalmology Times
FDA approval of YUVEZZI marks the first dual-agent, daily eye drop option for adults seeking non-invasive presbyopia treatment. (Image credit: Ophthalmology Times) The FDA has approved a fixed-dose ophthalmic combination of carbachol and brimonidine tartrate (YUVEZZI; Tenpoint Therapeutics) for the…
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation | Ophthalmology Times
(Image Credit: ADobeStock/New Africa) A large international study1 that evaluated the properties of dry eye drops showed that the commercially available formulations exhibited varying degrees of shear-thinning behavior, which affects the impact on the ocular surface. Ulrich Graf, PhD, the…
Dr. Mali’s top 5 predictions in ophthalmology for 2026 | Ophthalmology Times
From artificial intelligence to retinal care and postoperative protection, Joshua Mali, MD, FASRS, offers five predictions shaping ophthalmology in 2026. (Image credit: AdobeStock/Sam Efendi) It’s that exciting time of the year again when I reveal my top 5 predictions in…
SpyGlass Pharma randomizes first patients in 2 phase 3 clinical trials of the BIM-IOL System | Ophthalmology Times
(Image Credit: AdobeStock/Pixel-Shot) SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or…
Rayner announces Sophi Phaco System in the US | Ophthalmology Times
The FDA has given 501(k) clearance to Rayner’s Sophi (Swiss Ophthalmology Innovation) Phacoemulsification System, making it available to cataract surgeons in the US, according to the company.1 The platform was designed with a focus on mobility, simplicity, and safety, which…
Inside the clinic: Surgeon shares real-world experience | Ophthalmology Times
(Image Credit: AdobeStock) One of the most striking results with the Light Adjustable Lens (LAL; RxSight) is how quickly patients achieve excellent vision. With traditional IOLs, vision is expected to stabilize gradually over several days as the eye heals. With…